Therapeutic efficacy of tulathromycin, a novel triamilide antimicrobial, against bovine respiratory disease in feeder calves.
Efficacy and field safety of tulathromycin administered as a single-dose treatment to crossbreed beef calves with undifferentiated bovine respiratory disease (BRD) were evaluated in a multicenter field study conducted at four US feedlots. Two hundred castrated male calves were enrolled at each study site. The treatment groups were physiologic saline (n = 160) given SC at 0.02 ml/kg, tulathromycin (n = 320) given SC at 2.5 mg/kg, and tilmicosin (n = 320) given SC at 10 mg/kg. Nasopharyngeal swabs for bacterial culture were obtained before treatment. The cure rate for calves treated with tulathromycin (78%) and tilmicosin (65%) was significantly (P < or = .0001) higher than that of calves treated with saline (23.8%). The cure rate of calves treated with tulathromycin (78.4%) was significantly (P = .0007) higher than that of calves treated with tilmicosin (64.9%). No adverse events related to tulathromycin were reported. Under the conditions of this study, tulathromycin administered as a single-dose treatment was efficacious in the treatment of undifferentiated BRD.
Kilgore
W Randal
WR
Pfizer Animal Health, Veterinary Medicine Research and Development, Kalamazoo, MI 49001, USA.
Spensley
Michael S
MS
Sun
Fangshi
F
Nutsch
Robert G
RG
Rooney
Kathleen A
KA
Skogerboe
Terry L
TL
D000818:Animals; D000831:Animals, Newborn; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002417:Cattle; D004187:Disaccharides / Q000008:administration & dosage / Q000627:therapeutic use*; D006571:Heterocyclic Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D007279:Injections, Subcutaneous / Q000662:veterinary; D018942:Macrolides / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D009305:Nasopharynx / Q000382:microbiology; D012766:Pasteurellosis, Pneumonic / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome; D015645:Tylosin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D014481:United States
D000900:Anti-Bacterial Agents; D004187:Disaccharides; D006571:Heterocyclic Compounds; D018942:Macrolides; C485204:tulathromycin; C052319:tilmicosin; D015645:Tylosin